Related Experiment Video
Updated: Jun 28, 2025

Isolation of Mouse Primary Microglia by Magnetic-Activated Cell Sorting in Animal Models of Demyelination
Published on: April 5, 2022
Distinguishing microgliosis and tau deposition in the mouse brain using paramagnetic and diamagnetic susceptibility
Jayvik Joshi1,2, Minmin Yao3, Aaron Kakazu3
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract:
Tauopathies, including Alzheimer's disease (AD), are neurodegenerative disorders characterized by hyperphosphorylated tau protein aggregates in the brain. In addition to protein aggregates, microglia-mediated inflammation and iron dyshomeostasis are other pathological features observed in AD and other tauopathies. It is known that these alterations at the subcellular level occur much before the onset of macroscopic tissue atrophy or cognitive deficits. The ability to detect these microstructural changes with MRI therefore has substantive importance for improved characterization of disease pathogenesis. In this study, we demonstrate that quantitative susceptibility mapping (QSM) with paramagnetic and diamagnetic susceptibility source separation has the potential to distinguish neuropathological alterations in a transgenic mouse model of tauopathy. 3D multi-echo gradient echo data were acquired from fixed brains of PS19 (Tau) transgenic mice and age-matched wild-type (WT) mice (n = 5 each) at 11.7 T. The multi-echo data were fit to a 3-pool complex signal model to derive maps of paramagnetic component susceptibility (PCS) and diamagnetic component susceptibility (DCS). Group-averaged signal fraction and composite susceptibility maps showed significant region-specific differences between the WT and Tau mouse brains. Significant bilateral increases in PCS and |DCS| were observed in specific hippocampal and cortical sub-regions of the Tau mice relative to WT controls. Comparison with immunohistological staining for microglia (Iba1) and phosphorylated-tau (AT8) further indicated that the PCS and DCS differences corresponded to regional microgliosis and tau deposition in the PS19 mouse brains, respectively. The results demonstrate that quantitative susceptibility source separation may provide sensitive imaging markers to detect distinct pathological alterations in tauopathies.
Insights
Quantitative susceptibility mapping (QSM) can identify early brain changes in tauopathies, like Alzheimer's disease. This MRI technique detects microstructural alterations related to tau protein and inflammation before cognitive decline.
Area of Science:
- Neuroimaging
- Biophysics
- Neurodegeneration
Background:
- Tauopathies, including Alzheimer's disease (AD), are characterized by tau protein aggregates, neuroinflammation, and iron dyshomeostasis.
- These subcellular alterations precede macroscopic brain atrophy and cognitive deficits.
- Early detection of these microstructural changes is crucial for understanding disease pathogenesis.
Approach:
- Quantitative susceptibility mapping (QSM) with paramagnetic and diamagnetic susceptibility source separation was employed.
- 3D multi-echo gradient echo data were acquired from fixed brains of PS19 (Tau) transgenic and wild-type (WT) mice at 11.7 T.
- A 3-pool complex signal model was used to derive paramagnetic component susceptibility (PCS) and diamagnetic component susceptibility (DCS) maps.
Key Points:
- Significant region-specific differences in susceptibility maps were observed between Tau and WT mouse brains.
- Increased PCS and |DCS| were found in hippocampal and cortical regions of Tau mice.
- These susceptibility changes correlated with microgliosis (Iba1) and tau deposition (AT8) in the PS19 mouse model.
Conclusions:
- Quantitative susceptibility source separation shows potential for distinguishing neuropathological alterations in tauopathies.
- This technique may offer sensitive imaging markers for early detection of distinct pathological changes.
- The findings highlight QSM's utility in characterizing early-stage neurodegenerative disease processes.

